{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:39:16Z","timestamp":1793975956036,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373285"],"award-info":[{"award-number":["82373285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173837"],"award-info":[{"award-number":["82173837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61439-0","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:43:33Z","timestamp":1751546613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction"],"prefix":"10.1038","volume":"16","author":[{"given":"Zhen","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4097-9796","authenticated-orcid":false,"given":"Shiming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xincheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9143-5733","authenticated-orcid":false,"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-0965","authenticated-orcid":false,"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-7646","authenticated-orcid":false,"given":"Jiankai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"61439_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"61439_CR2","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok, G., Yau, T. C., Chiu, J. W., Tse, E. & Kwong, Y. L. Pembrolizumab (Keytruda). Hum. Vaccines Immunother. 12, 2777\u20132789 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"61439_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","volume":"19","author":"M Sznol","year":"2013","unstructured":"Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 19, 1021\u20131034 (2013).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"61439_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61439_CR5","doi-asserted-by":"publisher","first-page":"eaan4220","DOI":"10.1126\/scitranslmed.aan4220","volume":"9","author":"MC Brown","year":"2017","unstructured":"Brown, M. C. et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci. Transl. Med. 9, eaan4220 (2017).","journal-title":"Sci. Transl. Med."},{"key":"61439_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrclinonc.2015.106","volume":"12","author":"D Killock","year":"2015","unstructured":"Killock, D. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat. Rev. Clin. Oncol. 12, 438 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"61439_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","volume":"30","author":"W Hou","year":"2016","unstructured":"Hou, W., Sampath, P., Rojas, J. J. & Thorne, S. H. Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer cell 30, 108\u2013119 (2016).","journal-title":"Cancer cell"},{"key":"61439_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14340","volume":"8","author":"D Zamarin","year":"2017","unstructured":"Zamarin, D. et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat. Commun. 8, 14340 (2017).","journal-title":"Nat. Commun."},{"key":"61439_CR9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.immuni.2019.08.010","volume":"51","author":"G Kroemer","year":"2019","unstructured":"Kroemer, G. & Zitvogel, L. Leptin-producing oncolytic virus makes tumor-infiltrating T cells fit, not fat. Immunity 51, 423\u2013425 (2019).","journal-title":"Immunity"},{"key":"61439_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","volume":"51","author":"DB Rivadeneira","year":"2019","unstructured":"Rivadeneira, D. B. et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating t cell metabolism and promote tumor clearance. Immunity 51, 548\u2013560.e544 (2019).","journal-title":"Immunity"},{"key":"61439_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman, H. et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat. Med. 29, 450\u2013457 (2023).","journal-title":"Nat. Med."},{"key":"61439_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 41, 528\u2013540 (2023).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"61439_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119.e1110 (2017).","journal-title":"Cell"},{"key":"61439_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","volume":"27","author":"R Dummer","year":"2021","unstructured":"Dummer, R. et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat. Med. 27, 1789\u20131796 (2021).","journal-title":"Nat. Med."},{"key":"61439_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"61439_CR16","first-page":"48","volume":"55","author":"YY Li","year":"2017","unstructured":"Li, Y. Y. et al. From discovery to spread: the evolution and phylogeny of Getah virus. Infect., Genet. Evolution J. Mol. Epidemiol. Evolut. Genet. Infect. Dis. 55, 48\u201355 (2017).","journal-title":"Infect., Genet. Evolution J. Mol. Epidemiol. Evolut. Genet. Infect. Dis."},{"key":"61439_CR17","doi-asserted-by":"publisher","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","volume":"111","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl. Acad. Sci. USA 111, E4504\u2013E4512 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"61439_CR18","doi-asserted-by":"publisher","first-page":"eaam7996","DOI":"10.1126\/scitranslmed.aam7996","volume":"9","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 9, eaam7996 (2017).","journal-title":"Sci. Transl. Med."},{"key":"61439_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39156-3","volume":"14","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile. Nat. Commun. 14, 3410 (2023).","journal-title":"Nat. Commun."},{"key":"61439_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/hum.2016.038","volume":"27","author":"H Zhang","year":"2016","unstructured":"Zhang, H. et al. Naturally existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Hum. gene Ther. 27, 700\u2013711 (2016).","journal-title":"Hum. gene Ther."},{"key":"61439_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1089\/hum.2020.114","volume":"31","author":"J Cai","year":"2020","unstructured":"Cai, J. et al. Systematic characterization of the biodistribution of the oncolytic virus M1. Hum. Gene Ther. 31, 1203\u20131213 (2020).","journal-title":"Hum. Gene Ther."},{"key":"61439_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-022-00921-3","volume":"7","author":"D Song","year":"2022","unstructured":"Song, D. et al. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct. Target. Ther. 7, 100 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"61439_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101229","volume":"4","author":"J Dan","year":"2023","unstructured":"Dan, J. et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep. Med. 4, 101229 (2023).","journal-title":"Cell Rep. Med."},{"key":"61439_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03285-0","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis. 11, 1062 (2020).","journal-title":"Cell Death Dis."},{"key":"61439_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/cncr.24100","volume":"115","author":"AA Tarhini","year":"2009","unstructured":"Tarhini, A. A. et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859\u2013868 (2009).","journal-title":"Cancer"},{"key":"61439_CR26","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","volume":"12","author":"MJ Robertson","year":"2006","unstructured":"Robertson, M. J. et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12, 4265\u20134273 (2006).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"61439_CR27","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-07-4740","volume":"14","author":"MJ Robertson","year":"2008","unstructured":"Robertson, M. J. et al. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 14, 3462\u20133469 (2008).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"61439_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609\u2013614 (2020).","journal-title":"Nature"},{"key":"61439_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/hum.2020.273","volume":"32","author":"W Zhu","year":"2021","unstructured":"Zhu, W. et al. Real-time visualization and quantification of oncolytic M1 virus In vitro and in vivo. Hum. gene Ther. 32, 158\u2013165 (2021).","journal-title":"Hum. gene Ther."},{"key":"61439_CR30","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1016\/j.ymthe.2022.05.008","volume":"30","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Overcoming resistance to oncolytic virus M1 by targeting PI3K-\u03b3 in tumor-associated myeloid cells. Mol. Ther. J. Am. Soc. Gene Ther. 30, 3677\u20133693 (2022).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"61439_CR31","doi-asserted-by":"publisher","first-page":"e1009818","DOI":"10.1371\/journal.ppat.1009818","volume":"17","author":"LC de Jong","year":"2021","unstructured":"de Jong, L. C., Crnko, S., Ten Broeke, T. & Bovenschen, N. Noncytotoxic functions of killer cell granzymes in viral infections. PLoS Pathog. 17, e1009818 (2021).","journal-title":"PLoS Pathog."},{"key":"61439_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/cdd.2011.5","volume":"18","author":"LT Joeckel","year":"2011","unstructured":"Joeckel, L. T. et al. Mouse granzyme K has pro-inflammatory potential. Cell Death Differ. 18, 1112\u20131119 (2011).","journal-title":"Cell Death Differ."},{"key":"61439_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo0686","volume":"14","author":"AH Jonsson","year":"2022","unstructured":"Jonsson, A. H. et al. Granzyme K(+) CD8 T cells form a core population in inflamed human tissue. Sci. Transl. Med. 14, eabo0686 (2022).","journal-title":"Sci. Transl. Med."},{"key":"61439_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"61439_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri2959","volume":"11","author":"AN Akbar","year":"2011","unstructured":"Akbar, A. N. & Henson, S. M. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?. Nat. Rev. Immunol. 11, 289\u2013295 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"61439_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41590-024-02027-0","volume":"26","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1(+)CD8(+) T cells. Nat. Immunol. 26, 92\u2013104 (2025).","journal-title":"Nat. Immunol."},{"key":"61439_CR37","doi-asserted-by":"publisher","first-page":"eaba7918","DOI":"10.1126\/sciimmunol.aba7918","volume":"5","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci. Immunol. 5, eaba7918 (2020).","journal-title":"Sci. Immunol."},{"key":"61439_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg1094","volume":"9","author":"SA Minnie","year":"2024","unstructured":"Minnie, S. A. et al. TIM-3(+) CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies. Sci. Immunol. 9, eadg1094 (2024).","journal-title":"Sci. Immunol."},{"key":"61439_CR39","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.3389\/fmicb.2019.02246","volume":"10","author":"CM Figueiredo","year":"2019","unstructured":"Figueiredo, C. M. et al. Mayaro virus replication restriction and induction of muscular inflammation in mice are dependent on age, type-I interferon response, and adaptive immunity. Front. Microbiol. 10, 2246 (2019).","journal-title":"Front. Microbiol."},{"key":"61439_CR40","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.ymthe.2024.06.019","volume":"32","author":"TAH Hick","year":"2024","unstructured":"Hick, T. A. H. et al. Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo. Mol. Ther. J. Am. Soc. Gene Ther. 32, 2519\u20132534 (2024).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"61439_CR41","doi-asserted-by":"publisher","first-page":"e3354","DOI":"10.1371\/journal.pntd.0003354","volume":"8","author":"YS Poo","year":"2014","unstructured":"Poo, Y. S. et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Neglected Tropical Dis. 8, e3354 (2014).","journal-title":"PLoS Neglected Tropical Dis."},{"key":"61439_CR42","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859\u2013874 (2021).","journal-title":"Immunity"},{"key":"61439_CR43","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature04651","volume":"440","author":"F Castellino","year":"2006","unstructured":"Castellino, F. et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440, 890\u2013895 (2006).","journal-title":"Nature"},{"key":"61439_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: teammate or opponent in the tumour microenvironment?. Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"61439_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy, E., Carol, H., Ring, A. & Canna, S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat. Rev. Rheumatol. 20, 33\u201347 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"61439_CR46","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/0008-5472.CAN-15-1548","volume":"76","author":"GJ Markowitz","year":"2016","unstructured":"Markowitz, G. J. et al. Inflammation-dependent IL18 signaling restricts hepatocellular carcinoma growth by enhancing the accumulation and activity of tumor-infiltrating lymphocytes. Cancer Res. 76, 2394\u20132405 (2016).","journal-title":"Cancer Res."},{"key":"61439_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/cancers13020189","volume":"13","author":"LB Mutala","year":"2021","unstructured":"Mutala, L. B. et al. The caspase-1\/IL-18 axis of the inflammasome in tumor cells: a modulator of the Th1\/Tc1 response of tumor-infiltrating t lymphocytes in colorectal cancer. Cancers 13, 189 (2021).","journal-title":"Cancers"},{"key":"61439_CR48","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher, A., Harrington, K. & Vile, R. Oncolytic virotherapy as immunotherapy. Science 374, 1325\u20131326 (2021).","journal-title":"Science"},{"key":"61439_CR49","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"61439_CR50","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"61439_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.coi.2010.02.013","volume":"22","author":"JM Curtsinger","year":"2010","unstructured":"Curtsinger, J. M. & Mescher, M. F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22, 333\u2013340 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"61439_CR52","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.3389\/fimmu.2018.02987","volume":"9","author":"V Kalia","year":"2018","unstructured":"Kalia, V. & Sarkar, S. Regulation of effector and memory CD8 T cell differentiation by IL-2-A balancing act. Front. Immunol. 9, 2987 (2018).","journal-title":"Front. Immunol."},{"key":"61439_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41590-020-0628-2","volume":"21","author":"K Schober","year":"2020","unstructured":"Schober, K. et al. Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection. Nat. Immunol. 21, 434\u2013441 (2020).","journal-title":"Nat. Immunol."},{"key":"61439_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3905","volume":"15","author":"DC Tscharke","year":"2015","unstructured":"Tscharke, D. C., Croft, N. P., Doherty, P. C. & La Gruta, N. L. Sizing up the key determinants of the CD8(+) T cell response. Nat. Rev. Immunol. 15, 705\u2013716 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"61439_CR55","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.4049\/jimmunol.179.5.3203","volume":"179","author":"EK Day","year":"2007","unstructured":"Day, E. K. et al. Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus: human cytomegalovirus. J. Immunol. 179, 3203\u20133213 (2007).","journal-title":"J. Immunol."},{"key":"61439_CR56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"61439_CR57","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"61439_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12616","volume":"281","author":"G Kaplanski","year":"2018","unstructured":"Kaplanski, G. Interleukin-18: Biological properties and role in disease pathogenesis. Immunol. Rev. 281, 138\u2013153 (2018).","journal-title":"Immunol. Rev."},{"key":"61439_CR59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41422-020-00396-3","volume":"30","author":"KO Dixon","year":"2020","unstructured":"Dixon, K. O. & Kuchroo, V. K. IL-18: throwing off the shackles to boost anti-tumor immunity. Cell Res. 30, 831\u2013832 (2020).","journal-title":"Cell Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61439-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:40:57Z","timestamp":1757209257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61439-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61439"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61439-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, Ying Liu's first affiliation was incorrect and has now been amended to the Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6136"}}